Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert CofiledCriticalWarner Lambert Co
Priority to UY26560ApriorityCriticalpatent/UY26560A1/en
Publication of UY26560A1publicationCriticalpatent/UY26560A1/en
Este invento porporciona un método para preparar (S)-(+)-ácido 3-(aminometil)-5-metil-hexanoico (pregabalin) o una de sus sales por medio de una síntesis de hidrogenación asimétrica. El pregabalin es útil para el tratamiento y la prevención de trastornos causados por ataques (accesos), del dolor y trastornos psicóticos. El invento proporciona también compuestos intermedios útiles en la producción de pregabalin.This invention provides a method for preparing (S) - (+) - 3- (aminomethyl) -5-methyl-hexanoic acid (pregabalin) or one of its salts by means of an asymmetric hydrogenation synthesis. Pregabalin is useful for the treatment and prevention of disorders caused by seizures, pain and psychotic disorders. The invention also provides intermediates useful in the production of pregabalin.
UY26560A2001-01-252001-01-25
ASYMMETRIC SYNTHESIS OF PREGABALIN
UY26560A1
(en)
N4-phenylquinazoline-4-amine derivatives and related compounds as ERBB Type 1 receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases
Substituted amino alkano phosphonic acids for the treatment of neuropathic pain, affective and attention disorders, schizophrenia, tinnitus, myopia and other ocular disorders